Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination chemotherapy regimen consisting of methotrexate, 5-fluorouracil (5-FU), and leucovorin (also known as folinic acid). Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking DNA synthesis. 5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and disrupts DNA and RNA synthesis. Leucovorin is a reduced form of folic acid used to "rescue" normal cells from the toxic effects of methotrexate and to enhance the cytotoxicity of 5-fluorouracil by stabilizing its binding to thymidylate synthase. This combination has been used in various solid tumors including colorectal cancer[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methotrexate + 5-fluorouracil + leucovorin.